Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs MadeMed

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and MadeMed head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 21 · Grade B

MadeMed

Visit MadeMed Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 86 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make MadeMed a bad call — it's best for people comfortable prepaying at least three months who want to compare the exact charge for their prescribed route. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
92
Supply Reliability
95
84
Transparency
90
94
Access Breadth
93
76
Clinical Oversight
92
84
Track Record
88
82
CoreAge RxBrief Score 94 · 86MadeMed

Price, coverage & the tracker

CoreAge RxMadeMed
Brief Score94/100 (A)86/100 (B)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

$239/mo injectable

Quarterly prepay: $717 upfront; no monthly plan.

Sublingual: $219/mo, $657 upfront quarterly. Six-month options cost less.

Full price details

$239/mo injectable and $219/mo sublingual on the quarterly plan ($717 / $657 in one charge); $199 and $179 on the 6-month plan. No month-to-month option

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

$399/mo injectable

Quarterly prepay: $1,197 upfront; no monthly plan.

Sublingual: $299/mo, $897 upfront quarterly. Six-month options cost less.

Full price details

$399/mo injectable and $299/mo sublingual on the quarterly plan ($1,197 / $897 in one charge); $369 and $279 on the 6-month plan. No month-to-month option

CoverageUS only; restrictions by state, confirmed at intakeAvailability varies by treatment and state; confirm the selected product before prepaying
Brand-name accessNot confirmedNot confirmed
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

MadeMed: Each treatment route has a published price that stays the same across doses.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.